Li-Fraumeni Syndrome Imaging Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Whole body STIR MRI: Standard technique that detects abnormalities related to excess of water in tissues (edema).

DW-MRI: MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.

PET-MRI: MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.

Study summary

Li-Fraumeni Syndrome (LFS) is a cancer predisposition disorder in which most affected individuals develop cancer during their lifetime. The majority of LFS patients carry a mutation in a gene called TP53, whose normal function is to control cell growth and prevent cells with damaged DNA from becoming cancerous. There is currently no way to determine when, where or what type of tumour will develop. This project will use novel techniques utilizing magnetic resonance imaging (MRI) to determine how sensitive they are at detecting very small tumors and how specific they are in terms of distinguishing malignant tumors from benign tumors.

Eligibility

Primary outcome measure(s)

• Evaluation of imaging traits on suspected tumors — Through study completion, an average of 2 years
  Imaging traits include: signal heterogeneity, mass effect, and neurovascular bundle involvement (recorded on STIR MRI); necrosis, and signal/necrosis ratio (recorded on STIR and DW MRI): FDG metabolic activity and uptake (PET-MRI) or other additional imaging findings. Results will be combined and analyzed for "extraction" of imaging-gene expression phenotypes.

Trial sites (1)

More The Hospital for Sick Children trials in Canada